[May 27, 2015]

Research and Markets: Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015

Research and Markets (http://www.researchandmarkets.com/research/gdw7kx/exocrine) has announced the addition of the "Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key layers involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Actavis plc
• Anthera Pharmaceuticals Inc.
• Cilian AG
• Laboratoires Mayoly Spindler S.A.S.
• Nordmark Arzneimittel GmbH & Co. KG
  

Drug Profiles

• burlulipase
• Cilase
• Enzyme to Replace Lipase for Exocrine Pancreatic Insufficiency
• liprotamase
• MS-1819
• pancrelipase DR

For more information visit http://www.researchandmarkets.com/research/gdw7kx/exocrine

View source version on businesswire.com: http://www.businesswire.com/news/home/20150527006287/en/

[ Back To TMCnet.com's Homepage ]